低剂量放疗通过促进T细胞浸润与iRGD-antiCD3修饰T细胞协同增效
该研究在胃癌腹膜转移小鼠模型中探讨低剂量放疗与iRGD-antiCD3修饰T细胞的协同作用。2 Gy照射上调三种iRGD受体及T细胞趋化因子表达,促进修饰T细胞在腹膜肿瘤结节中的聚集与浸润;联合治疗显著抑制肿瘤生长并延长生存,安全性良好。
要点
- 2 Gy照射上调三种iRGD受体和T细胞趋化因子的表达。
- 2 Gy照射促进iRGD-antiCD3修饰T细胞在腹膜肿瘤结节中的聚集和浸润。
- 2 Gy联合iRGD-antiCD3修饰T细胞显著抑制小鼠腹膜转移瘤生长并延长生存,安全性良好。
核心结论
- 低剂量放疗可通过促进T细胞浸润提高iRGD-antiCD3修饰T细胞的抗肿瘤效力,为在实体瘤中探索低剂量放疗联合其他过继性T细胞疗法提供依据。
研究设计与样本
- 在胃癌腹膜转移小鼠模型中开展实验研究,采用流式细胞术评估iRGD受体与趋化因子表达,用免疫组织荧光和体内实时荧光成像评估T细胞浸润,用体内生物发光成像评估抗肿瘤效果。
主要发现
- 2 Gy照射上调全部三种iRGD受体和T细胞趋化因子的表达。
- 2 Gy低剂量照射促进iRGD-antiCD3修饰T细胞在腹膜肿瘤结节中的聚集和浸润。
- 2 Gy低剂量照射联合iRGD-antiCD3修饰T细胞显著抑制腹膜转移小鼠模型肿瘤生长并延长生存,安全性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Poor penetration of transferred T cells represents a critical factor impeding the development of adoptive cell therapy in solid tumors. We demonstrated that iRGD-antiCD3 modification promoted both T cell infiltration and activation in our previous work. Interest in low-dose radiotherapy has recently been renewed due to its immuno-stimulatory effects including T cell recruitment. This study aims to explore the synergistic effects between low-dose radiotherapy and iRGD-antiCD3-modified T cells. MATERIALS AND METHODS: Flow cytometry was performed to assess the expression of iRGD receptors and chemokines. T cell infiltration was evaluated by immunohistofluorescence and in vivo real-time fluorescence imaging and antitumor effects were investigated by in vivo bioluminescence imaging in the gastric cancer peritoneal metastasis mouse model. RESULTS: We found that 2 Gy irradiation upregulated the expression of all three iRGD receptors and T-cell chemokines. The addition of 2 Gy low-dose irradiation boosted the accumulation and penetration of iRGD-antiCD3-modified T cells in peritoneal tumor nodules. Combining 2 Gy low-dose irradiation with iRGD-antiCD3-modified T cells significantly inhibited tumor growth and prolonged survival in the peritoneal metastasis mouse model with a favorable safety profile. CONCLUSION: Altogether, we demonstrated that low-dose radiotherapy could improve the antitumor potency of iRGD-antiCD3-modified T cells by promoting T cell infiltration, providing a rationale for exploring low-dose radiotherapy in combination of other adoptive T cell therapies in solid tumors.
引用
- Zhou S, Zhu M, Wei X, et al. Low-dose radiotherapy synergizes with iRGD-antiCD3-modified T cells by facilitating T cell infiltration. Radiother Oncol. 2024. PMID: 38458258. doi:10.1016/j.radonc.2024.110213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。